Condition
Overweight
Obesity
Type 2 Diabetes
Locations
United States
Start date
08/10/2026
Identifiers
Trial ID NN9490-8554,
NCT number NCT07868354,
Eudract number Not Available
NCT number NCT07868354,
Eudract number Not Available
Summary
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get tirzepatide and zenagamtide.
Trial Overview:
Treatment
DRUG: Tirzepatide
DRUG: Zenagamtide
Study type
INTERVENTIONAL
Trial duration
Oct 08 2026 - Sep 07 2028
Participants
60
Phase
I
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.